Saturday 17 October 2026
Export CRMD’s income statement to Excel — free account
CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
7.26
0.20
−2.68%
Follow CRMD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 5 | 4 | 3 | 4 | 4 | 3 |
P/E ratio |
5.26 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.15 | 4.93 | — | 7.80 | 11.40 | 18.12 | 7.43 | (12.34) | (20.62) | (1.85) |
P/S ratio |
2.69 | 10.96 | — | 2,574.09 | 897.28 | 887.19 | 620.64 | 267.37 | 88.72 | 289.71 |
P/FCF ratio |
4.85 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.07 | (3.52) | — | (3.87) | 2.06 | (3.10) | (16.91) | (36.41) | (48.70) | (15.45) |
Beneish M-Score |
12.80 | — | — | — | 11.52 | — | — | (0.03) | (2.99) | — |
P/Operating CF |
8.87 | (84.93) | — | (27.35) | (29.20) | (35.77) | (45.26) | (15.96) | (4.02) | (9.99) |
P/B ratio |
2.07 | 5.63 | — | 3.06 | 2.73 | 4.80 | 7.44 | 23.29 | 4.06 | 3.64 |
Price to Tangible BV |
0.00 | 5.76 | — | 3.06 | 2.73 | 4.80 | 7.44 | 23.29 | 4.06 | 3.64 |
EV/Sales |
2.68 | 9.79 | — | 1,683.43 | 558.04 | 696.40 | 519.95 | 240.22 | 51.82 | 198.96 |
EV/EBITDA |
5.04 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
4.76 | (8.41) | — | (4.52) | (5.04) | (7.58) | (9.79) | (4.36) | (0.60) | (2.00) |
EV/FCF |
4.83 | (8.39) | — | (4.48) | (4.72) | (7.54) | (9.76) | (4.35) | (0.59) | (2.00) |
Quick Ratio |
1.83 | 3.05 | 6.68 | 9.34 | 12.28 | 11.19 | 4.90 | 2.29 | 1.95 | 4.97 |
Current Ratio |
2.11 | 3.39 | 6.97 | 9.44 | 12.44 | 11.58 | 5.04 | 2.40 | 2.12 | 5.34 |
Net Debt/EBITDA |
(0.02) | 2.36 | 1.56 | 1.92 | 2.21 | 1.69 | 1.38 | 0.44 | 0.37 | 0.82 |
Debt/Assets |
17.58% | 0.00% | 0.00% | 1.08% | 1.16% | 1.87% | 0.01% | 32.54% | 0.00% | 0.00% |
Debt/Equity |
0.36 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 | 1.24 | 0.00 | 0.00 |
Asset Turnover |
0.66 | 0.43 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.02 | 0.01 |
Operating CF/Net income |
1.07 | 2.82 | 0.83 | 0.82 | 0.75 | 1.00 | 0.35 | 0.88 | 0.87 | 0.90 |
Capex/Depreciation |
(0.15) | (0.25) | (1.59) | (1.05) | (8.05) | (0.69) | (0.09) | (0.66) | (4.12) | (2.29) |
Interest Coverage |
53.97 | (621.00) | (1,427.34) | (1,155.62) | (1,851.42) | (819.90) | (26.68) | (14,139.05) | (5,879.30) | (19,046.85) |
| 66.56% | (23.17%) | (74.02%) | (50.40%) | (52.72%) | (64.91%) | (304.66%) | (442.49%) | (264.01%) | (95.10%) | |
| 34.51% | (17.85%) | (64.32%) | (45.35%) | (47.71%) | (55.92%) | (180.27%) | (166.23%) | (186.71%) | (83.53%) | |
ROIC |
23.34% | (42.38%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
82.04% | (21.72%) | (66.28%) | (54.15%) | (45.07%) | (49.91%) | (184.13%) | (242.59%) | (458.89%) | (138.37%) |
Average Days of Receivables |
200.51 | 433.70 | — | 0.00 | 86.80 | 5.19 | 0.00 | 9.26 | 71.05 | 19.54 |
Research and Development Expense of Revenue |
6.20% | 9.07% | 0.00% | 16,329.66% | 6,879.52% | 5,592.47% | 3,901.48% | 4,379.36% | 7,435.80% | 7,021.55% |
Selling, General and Administrative Expense of Revenue |
34.09% | 135.02% | 0.00% | 30,590.37% | 8,562.91% | 5,801.80% | 3,482.17% | 1,878.71% | 2,627.51% | 3,963.90% |
Intangible Assets out of Total Assets |
0.50 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
4.44% | 14.10% | 0.00% | 6,222.48% | 2,641.49% | 1,045.07% | 861.14% | 258.40% | 503.83% | 595.81% |
Graham Net Nets |
(0.06) | 0.17 | — | 0.31 | 0.35 | 0.20 | 0.13 | 0.04 | 0.24 | 0.27 |
Graham Number |
16.73 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
19.00% | (4.07%) | — | (17.70%) | (16.26%) | (10.23%) | (9.33%) | (25.58%) | (115.09%) | (37.43%) |
Free Cash Flow Yield |
20.62% | (10.64%) | — | (14.60%) | (13.18%) | (10.40%) | (8.58%) | (20.67%) | (98.34%) | (34.39%) |
Revenue per Share |
4.33 | 0.74 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 |
Operating CF per Share |
2.43 | (0.86) | (0.75) | (0.60) | (0.56) | (0.77) | (0.62) | (1.33) | (2.59) | (2.93) |
Capex per Share |
(0.03) | 0.00 | (0.01) | (0.01) | (0.04) | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) |
Free Cash Flow per Share |
2.40 | (0.86) | (0.76) | (0.61) | (0.60) | (0.77) | (0.62) | (1.33) | (2.61) | (2.94) |
Cash per Share |
2.06 | 0.88 | 1.50 | 1.46 | 1.74 | 1.63 | 1.18 | 1.00 | 1.10 | 2.68 |
Shareholders Equity per Share |
5.63 | 1.44 | 1.38 | 1.37 | 1.67 | 1.55 | 0.98 | 0.28 | 0.65 | 2.35 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.63 | 1.44 | 1.38 | 1.37 | 1.67 | 1.55 | 0.98 | 0.28 | 0.65 | 2.35 |
Free Cash Flow |
172.79 | (50.73) | (38.74) | (24.58) | (22.58) | (22.08) | (15.09) | (23.75) | (28.74) | (22.32) |
Working Capital |
192.78 | 80.74 | 68.05 | 53.24 | 61.12 | 44.02 | 23.52 | 10.90 | 7.01 | 17.74 |
Capital Expenditures |
(2.26) | (0.12) | (0.33) | (0.22) | (1.43) | (0.11) | (0.04) | (0.05) | (0.15) | (0.06) |
Net Current Asset Value |
(53.78) | 80.39 | 67.53 | 52.57 | 60.32 | 43.10 | 23.52 | 4.77 | 7.01 | 17.74 |
EV/EBIT |
5.55 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.00 | 0.00 | 3.35 | 7.47 | 0.47 | 0.13 | 0.11 | 0.46 | 0.26 |
Price to Operating Income |
5.58 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.58 | 0.25 | 0.11 | 0.13 | 0.12 | 1.46 | 3.16 | 0.46 | 0.20 | 0.37 |
Cash ROIC |
24.72% | (37.21%) | (26.49%) | (21.44%) | (17.48%) | (24.08%) | (28.92%) | (82.31%) | (148.53%) | (58.51%) |
Accounts Receivable Turnover |
2.80 | 1.68 | — | 0.00 | 7.82 | 140.71 | 51.98 | 11.46 | 8.65 | 1.37 |
Accounts Payable Turnover |
7.49 | 1.06 | 0.00 | 0.00 | 0.09 | 0.19 | 0.21 | 0.18 | 0.07 | 0.22 |
Inventory Turnover |
1.93 | 0.66 | 0.00 | 0.00 | 2.03 | 0.85 | 0.97 | 0.78 | 0.30 | 1.35 |
Average Days of Payables |
80.02 | 196.80 | 0.00 | 217,234.19 | 5,416.41 | 2,010.53 | 1,001.79 | 2,381.51 | 5,739.39 | 1,637.67 |
Days of Inventory on Hand |
301.61 | 869.59 | 0.00 | 0.00 | 7.35 | 255.93 | 331.06 | 394.16 | 1,885.94 | 165.93 |
Average Receivables |
111.44 | 25.85 | — | — | 0.02 | 0.00 | 0.01 | 0.04 | 0.04 | 0.16 |
Average Payables |
4.80 | 3.00 | 3.24 | 2.21 | 1.67 | 1.08 | 1.81 | 2.20 | 1.73 | 1.68 |
Average Inventory |
18.66 | 4.85 | 1.05 | — | 0.07 | 0.24 | 0.38 | 0.51 | 0.38 | 0.27 |
Average Assets |
472.49 | 100.45 | 72.05 | 65.49 | 59.13 | 39.39 | 24.15 | 16.14 | 17.68 | 29.50 |
Average Common Equity |
244.98 | 77.40 | 62.60 | 58.93 | 53.51 | 33.93 | 14.29 | 6.06 | 12.50 | 25.91 |
Columns are period end dates